High-dose desvenlafaxine in outpatients with major depressive disorder.

CNS spectrums 20120901

An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator.

CNS spectrums 20120901

Field and laboratory studies of the fate and enantiomeric enrichment of venlafaxine and O-desmethylvenlafaxine under aerobic and anaerobic conditions.

Chemosphere 20120601

A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression.

Nordic journal of psychiatry 20120601

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

European journal of clinical pharmacology 20120501

Effective and clinically meaningful non-hormonal hot flash therapies.

Maturitas 20120501

Impact of wastewater treatment plant discharge of lidocaine, tramadol, venlafaxine and their metabolites on the quality of surface waters and groundwater.

Journal of environmental monitoring : JEM 20120501

Occurrence of Tako-Tsubo cardiomyopathy in association with ingestion of serotonin/noradrenaline reuptake inhibitors.

Heart, lung & circulation 20120401

Occurrence and removal of lidocaine, tramadol, venlafaxine, and their metabolites in German wastewater treatment plants.

Environmental science and pollution research international 20120301

Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice.

Drug metabolism and disposition: the biological fate of chemicals 20120301

The effect of dose titration and dose tapering on the tolerability of desvenlafaxine in women with vasomotor symptoms associated with menopause.

Journal of women's health (2002) 20120201

Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.

Climacteric : the journal of the International Menopause Society 20120201

Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.

Forensic science international 20120110

Assessing the relationship between functional impairment/recovery and depression severity: a pooled analysis.

International clinical psychopharmacology 20120101

Duloxetine versus other anti-depressive agents for depression.

The Cochrane database of systematic reviews 20120101

Desvenlafaxine in the treatment of major depressive disorder.

Expert opinion on pharmacotherapy 20111201

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.

Neuroscience 20111124

Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms.

Clinical toxicology (Philadelphia, Pa.) 20111101

Inhibitory effects of desvenlafaxine on gastric slow waves, antral contractions, and gastric accommodation mediated via the sympathetic mechanism in dogs.

American journal of physiology. Gastrointestinal and liver physiology 20111001

Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.

Journal of clinical psychopharmacology 20111001

Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in nonresponders and responders.

Current medical research and opinion 20110901

A simple HPLC method for the simultaneous determination of venlafaxine and its major metabolite O-desmethylvenlafaxine in human serum.

Bioanalysis 20110801

Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.

International journal of legal medicine 20110501

Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.

Biopharmaceutics & drug disposition 20110501

A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants.

Journal of affective disorders 20110401

Antidepressant-mediated gastroesophageal reflux disease.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20110401

Tolerance to desvenlafaxine in rapid metabolizing depressed patients.

International clinical psychopharmacology 20110301

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

CNS drugs 20110301

Estimation of desvenlafaxine transfer into milk and infant exposure during its use in lactating women with postnatal depression.

Archives of women's mental health 20110201

Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110101

The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment.

International journal of clinical pharmacology and therapeutics 20110101

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.

Clinical drug investigation 20110101

Comments on 'Desvenlafaxine as a possible cause of acquired hemophilia'.

General hospital psychiatry 20110101

Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression.

Therapeutic drug monitoring 20101201

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.

Expert opinion on drug metabolism & toxicology 20101201

Stereoselective determination of venlafaxine and its three demethylated metabolites in human plasma and whole blood by liquid chromatography with electrospray tandem mass spectrometric detection and solid phase extraction.

Journal of pharmaceutical and biomedical analysis 20101102

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder.

The Journal of clinical psychiatry 20101101

HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder.

Pharmacopsychiatry 20101101

Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.

European journal of clinical pharmacology 20100901

Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.

Journal of clinical psychopharmacology 20100801

Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.

Drugs & aging 20100801

Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.

The Journal of clinical psychiatry 20100801

Antidepressant 'treatment'.

Menopause (New York, N.Y.) 20100701

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.

Menopause (New York, N.Y.) 20100701

Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder.

Journal of clinical psychopharmacology 20100601

Desvenlafaxine: a therapeutic option for treatment of menopausal hot flashes.

Maturitas 20100501

Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100301

Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials.

CNS spectrums 20100301

Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.

Journal of clinical psychopharmacology 20100201

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Current medical research and opinion 20100101

Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.

Journal of psychiatric practice 20100101

Mania possibly induced by desvenlafaxine.

Journal of psychiatric practice 20100101

Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.

Postgraduate medicine 20100101

Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome.

CNS spectrums 20100101

Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.

Primary care companion to the Journal of clinical psychiatry 20100101

Desvenlafaxine as a possible cause of acquired hemophilia.

General hospital psychiatry 20100101

IFN-gamma reduction by tricyclic antidepressants.

International journal of psychiatry in medicine 20100101

Rapid high-performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of venlafaxine and O-desmethylvenlafaxine in human plasma and its application in comparative bioavailability study.

Biomedical chromatography : BMC 20091201

Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder.

International clinical psychopharmacology 20091101

Simultaneous determination of venlafaxine and its main active metabolite O-desmethyl venlafaxine in rat plasma by LC-MS/MS.

Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20091001

Desvenlafaxine: application withdrawal. Desvenlafaxine: withdrawal of marketing application for depression also.

Prescrire international 20091001

[Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].

Ginecologia y obstetricia de Mexico 20091001

Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.

The Journal of clinical psychiatry 20091001

Venlafaxine in human breast milk and nursing infant plasma: determination of exposure.

The Journal of clinical psychiatry 20090901

Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status.

Journal of clinical psychopharmacology 20090801

Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.

Clinical therapeutics 20090601

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.

Clinical therapeutics 20090601

Desvenlafaxine: a new antidepressant or just another one?

Expert opinion on pharmacotherapy 20090401

New drug update: 2008.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20090401

Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety.

American journal of obstetrics and gynecology 20090301

The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults.

Journal of clinical pharmacology 20090201

A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.

American journal of obstetrics and gynecology 20090201

Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.

Journal of clinical psychopharmacology 20090201

Drug approvals: '08 in review. Desvenlafaxine (Pristiq).

The Nurse practitioner 20090201

Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.

Current opinion in investigational drugs (London, England : 2000) 20090101

A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder.

CNS spectrums 20090101

Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.

Psychopharmacology bulletin 20090101

Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo.

Psychopharmacology bulletin 20090101

An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.

Drug metabolism and disposition: the biological fate of chemicals 20081201

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.

Expert review of neurotherapeutics 20081201

Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.

Journal of psychiatric practice 20081101

Desvenlafaxine: another 'me too' drug?

The Annals of pharmacotherapy 20081001

Desvenlafaxine succinate for the treatment of major depressive disorder.

Expert opinion on pharmacotherapy 20080801

Liquid chromatography tandem mass spectrometry assay for the simultaneous determination of venlafaxine and O-desmethylvenlafaxine in human plasma and its application to a bioequivalence study.

Journal of pharmaceutical and biomedical analysis 20080715

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Current medical research and opinion 20080701

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder.

International clinical psychopharmacology 20080701

Flat dose-response curves for efficacy: what do they mean to the clinician?

Journal of psychiatric practice 20080701

Desvenlafaxine succinate for major depressive disorder.

Drugs of today (Barcelona, Spain : 1998) 20080701

Desvenlafaxine for depression.

The Medical letter on drugs and therapeutics 20080519

Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele.

European journal of clinical pharmacology 20080501

Desvenlafaxine succinate monohydrate.

Acta crystallographica. Section C, Crystal structure communications 20080501

Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.

Clinical pharmacology and therapeutics 20080201

Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.

Obstetrics and gynecology 20080101

Identifying meaningful differences in vasomotor symptoms among menopausal women.

Menopause (New York, N.Y.) 20080101

New drugs: Etravirine, sinecatechins, and desvenlafaxine succinate.

Journal of the American Pharmacists Association : JAPhA 20080101

Desvenlafaxine extended release.

CNS drugs 20080101

Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.

The Journal of pharmacology and experimental therapeutics 20071101

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.

International clinical psychopharmacology 20071101

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.

The Journal of clinical psychiatry 20071101

New products and regimens (since 2003).

Climacteric : the journal of the International Menopause Society 20071001

Analysis of the second generation antidepressant venlafaxine and its main active metabolite O-desmethylvenlafaxine in human plasma by HPLC with spectrofluorimetric detection.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901

Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder.

Journal of child and adolescent psychopharmacology 20070801

Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in human plasma by HPLC-ESI/MS using a vancomycin chiral column.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.

The Journal of clinical psychiatry 20070501

Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models.

Endocrinology 20070301

Employing atmospheric pressure photoionization in liquid chromatography/tandem mass spectrometry to minimize ion suppression and matrix effects for the quantification of venlafaxine and O-desmethylvenlafaxine.

Rapid communications in mass spectrometry : RCM 20070101

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

Journal of clinical pharmacy and therapeutics 20061001

Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.

The Journal of pharmacology and experimental therapeutics 20060801

Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats.

Brain research 20060707

CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.

International journal of geriatric psychiatry 20060601

[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].

No to shinkei = Brain and nerve 20060601

Anesthesiologist suicide with atracurium.

Journal of analytical toxicology 20060301

Liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for simultaneous determination of venlafaxine and its active metabolite O-desmethyl venlafaxine in human plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051227

Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.

Journal of chromatography. A 20051209

Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.

Therapeutic drug monitoring 20050801

Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.

International journal of geriatric psychiatry 20041201

Quantification of venlafaxine and O-desmethylvenlafaxine in human serum using HPLC analysis.

International journal of clinical pharmacology and therapeutics 20041201

Time course of clinical response to venlafaxine: relevance of plasma level and chirality.

European journal of clinical pharmacology 20040201

A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.

Journal of clinical psychopharmacology 20031201

Inhibition of P-glycoprotein by newer antidepressants.

The Journal of pharmacology and experimental therapeutics 20030401

Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting.

Therapeutic drug monitoring 20020801

Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.

European journal of clinical pharmacology 20020801

Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants.

British journal of clinical pharmacology 20020101

Venlafaxine in neuropathic pain following treatment of breast cancer.

European journal of pain (London, England) 20020101

False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine.

Clinical chemistry 20020101

Venlafaxine and breast-feeding.

The American journal of psychiatry 20011201

Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications.

Journal of chromatography. B, Biomedical sciences and applications 20010905

Use of vancomycin silica stationary phase in packed capillary electrochromatography. II. Enantiomer separation of venlafaxine and O-desmethylvenlafaxine in human plasma.

Journal of chromatography. A 20010601

Nonaqueous capillary electrophoresis-mass spectrometry for separation of venlafaxine and its phase I metabolites.

Electrophoresis 20010201